| Autor: |
Galal Yahya, Nashwa Hashem Mohamed, Jordi Pijuan, Noura M. Seleem, Rasha Mosbah, Steffen Hess, Ahmed A. Abdelmoaty, Rafa Almeer, Mohamed M. Abdel‐Daim, Hamoud Shulaywih Alshaman, Ibrahim Juraiby, Kamel Metwally, Zuzana Storchova |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Microbial Biotechnology, Vol 14, Iss 5, Pp 2199-2213 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1751-7915 |
| DOI: |
10.1111/1751-7915.13904 |
| Popis: |
Summary Sofosbuvir and Daclatasvir are among the direct‐acting antiviral (DAA) medications prescribed for the treatment of chronic hepatitis C (CHC) virus infection as combination therapy with other antiviral medications. DAA‐based therapy achieves high cure rates, reaching up to 97% depending on the genotype of the causative hepatitis C virus (HCV). While DAAs have been approved as an efficient and well‐tolerated therapy for CHC, emerging concerns about adverse cardiac side effects, higher risk of recurrence and occurrence of hepatocellular carcinoma (HCC) and doubts of genotoxicity have been reported. In our study, we investigated in detail physiological off‐targets of DAAs and dissected the effects of these drugs on cellular organelles using budding yeast, a unicellular eukaryotic organism. DAAs were found to disturb the architecture of the endoplasmic reticulum (ER) and the mitochondria, while showing no apparent genotoxicity or DNA damaging effect. Our study provides evidence that DAAs are not associated with genotoxicity and highlights the necessity for adjunctive antioxidant therapy to mitigate the adverse effects of DAAs on ER and mitochondria. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
